ALK and non-small cell lung carcinoma: To our knowledge, this is the first study worldwide to analyze the cost-effectiveness of a novel anticancer drug (lorlatinib) vs a standard-of-care drug (crizotinib) for the treatment of advanced ALK + NSCLC.